Nkarta Inc (NAS:NKTX)
$ 2.87 -0.12 (-4.01%) Market Cap: 202.53 Mil Enterprise Value: 4.93 Mil PE Ratio: 0 PB Ratio: 0.47 GF Score: 38/100

Nkarta Inc at Cowen Oncology Innovation Summit: Insights for ASCO & EHA (Virtual) Transcript

Jun 02, 2022 / 03:00PM GMT
Release Date Price: $14.31 (+5.14%)
Yaron Werber
Cowen and Company, LLC - Analyst

Well, good morning, everybody, and thank you once again for joining us for the 3rd Annual Oncology Innovation Summit. I am Yaron Werber, one of the biotech analysts at Cowen. And it's a great pleasure to have with us today Paul Hastings, President and CEO of Nkarta Therapeutics.

Paul, great to see you. Thanks for joining.

Paul Hastings
Nkarta, Inc. - CEO

Thanks, Yaron. Nice to be here.

Yaron Werber
Cowen and Company, LLC - Analyst

So lots to talk about on the heels of the recent data with NKX101 both in AML and in NHL. So maybe for the audience just by way of background recall, this was the initial Phase 1 data across all doses in AML patients.

The ORR was 47% or 8 out of 17, including 18% complete response rates but that's across all doses. The relevant doses are 1 billion and 1.5 billion where they can get up to three doses, at least that is the data we saw.

And here they had a 60% response rate, 3 out of 5 complete response rate with

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot